CRIS Current Research Information System

ZACCHERINI, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.529
NA - Nord America 4.582
EU - Europa 3.246
SA - Sud America 359
AF - Africa 287
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.482
VN - Vietnam 2.452
SG - Singapore 1.447
CN - Cina 1.264
IT - Italia 911
HK - Hong Kong 506
GB - Regno Unito 454
SE - Svezia 382
DE - Germania 350
BR - Brasile 234
FR - Francia 214
IN - India 207
KR - Corea 166
NL - Olanda 158
FI - Finlandia 144
RU - Federazione Russa 111
IE - Irlanda 108
JP - Giappone 99
CI - Costa d'Avorio 78
TG - Togo 76
CH - Svizzera 72
BG - Bulgaria 69
PH - Filippine 57
ZA - Sudafrica 55
CA - Canada 53
JO - Giordania 46
AT - Austria 45
UA - Ucraina 43
AR - Argentina 41
ES - Italia 41
MX - Messico 35
BD - Bangladesh 33
ID - Indonesia 33
TH - Thailandia 33
PL - Polonia 31
IQ - Iraq 30
EC - Ecuador 27
EE - Estonia 24
PK - Pakistan 21
TR - Turchia 20
BE - Belgio 19
CO - Colombia 19
SA - Arabia Saudita 18
IR - Iran 16
TW - Taiwan 15
SC - Seychelles 14
HR - Croazia 13
EG - Egitto 12
CL - Cile 11
LT - Lituania 11
MY - Malesia 11
UZ - Uzbekistan 11
VE - Venezuela 11
NG - Nigeria 10
NP - Nepal 10
CZ - Repubblica Ceca 8
HU - Ungheria 7
AL - Albania 6
KE - Kenya 6
PY - Paraguay 6
RS - Serbia 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
CD - Congo 5
DZ - Algeria 5
MA - Marocco 5
PE - Perù 5
AU - Australia 4
CR - Costa Rica 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
RO - Romania 4
AM - Armenia 3
IL - Israele 3
MU - Mauritius 3
OM - Oman 3
PS - Palestinian Territory 3
SN - Senegal 3
UY - Uruguay 3
AZ - Azerbaigian 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
GH - Ghana 2
GR - Grecia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MD - Moldavia 2
MG - Madagascar 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
VA - Santa Sede (Città del Vaticano) 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CU - Cuba 1
CY - Cipro 1
Totale 14.999
Salva come PNG Salva come JPEG
Città #
Singapore 1.036
Ashburn 595
Ho Chi Minh City 525
Hanoi 492
Hong Kong 454
Southend 357
Dong Ket 340
Fairfield 336
Chandler 324
Hefei 308
San Jose 259
Bologna 218
Santa Clara 212
Woodbridge 158
Houston 156
Los Angeles 151
Seoul 141
Wilmington 133
Beijing 132
Seattle 125
Cambridge 121
Da Nang 113
Helsinki 112
Princeton 112
Dublin 106
Ann Arbor 105
Boardman 105
Dallas 96
Lauterbourg 81
Tokyo 79
Abidjan 78
Lomé 76
Milan 71
New York 69
Sofia 68
Bern 65
Council Bluffs 64
Haiphong 56
Frankfurt am Main 47
Amman 45
Munich 39
Guangzhou 37
Bengaluru 34
Berlin 34
Nanjing 33
Westminster 33
Biên Hòa 32
Redondo Beach 32
Nuremberg 31
Buffalo 29
Shenyang 29
Jinan 28
Padova 28
Hải Dương 27
San Diego 27
São Paulo 27
London 26
Rome 26
Vienna 26
Turin 25
Orem 24
Amsterdam 23
Can Tho 23
Florence 23
Zhengzhou 23
Johannesburg 22
Shanghai 21
Vũng Tàu 21
Warsaw 21
Jakarta 20
Toronto 20
Thái Nguyên 19
Tianjin 19
Lappeenranta 18
Bangkok 17
Des Moines 17
Redmond 17
Chennai 16
Hebei 16
Ninh Bình 16
Bến Tre 15
Changsha 15
Hangzhou 15
Saint Petersburg 15
Xi'an 15
Brussels 14
Falkenstein 14
Paris 14
Turku 14
Casalecchio di Reno 13
Denver 13
Modena 13
Montreal 13
Quận Bình Thạnh 13
Bremen 12
Mexico City 12
Tongling 12
Tân Tiến 12
Atlanta 11
Baghdad 11
Totale 9.386
Salva come PNG Salva come JPEG
Nome #
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 478
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 424
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 360
OS-077 Single-cell RNA sequencing of peripheral blood mononuclear cells in patients with acutely decompensated cirrhosis reveals a specific monocyte subset associated with an increased risk of progression to ACLF 349
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment 262
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 260
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 254
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 252
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register 252
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 250
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 241
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 239
A case of pneumonia and sepsis in cirrhosis as paradigm of the problems in the management of bacterial infections in cirrhosis and of the limitations of current knowledge 232
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF 229
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications 221
Low haemoglobin level predicts early hospital readmission in patients with cirrhosis and acute decompensation 215
Albumin administration in internal medicine: A journey between effectiveness and futility 212
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 208
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register 203
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 200
Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study 198
Outcomes of patients with alcohol-related cirrhosis referred to a hepatology outpatient clinic 198
Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET) 191
Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study) 190
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure 189
The analysis of food intake in patients with cirrhosis waiting for liver transplantation: A neglected step in the nutritional assessment 188
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis 187
A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman 185
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial 183
Need for deprescribing in hospital elderly patients discharged with a limited life expectancy: The REPOSI study 178
A Case of Immune-Mediated Liver Injury Induced by Olaparib 177
Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. 175
Acute-on-chronic liver failure is a distinct syndrome developing in patients with acute dcompensation of cirrhosis. 175
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. 173
Incidence and clinical implications of abstinence-induced hepatic recompensation in decompensated alcohol-related cirrhosis 172
The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis 171
Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study 171
Disorders of albumin metabolism in liver diseases. 171
Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients 170
QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? 169
Role of human albumin in the management of complications of liver cirrhosis. 168
Assessing the role of amino acids in systemic inflammation and organ failure in patients with {ACLF} 166
Human albumin in the management of complications of liver cirrhosis. 158
Development and validation of a prognostic score to predict mortality in patients with acute on chronic liver failure. 157
Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation 156
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis 154
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis 153
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis 149
Patients with cirrhosis and ascites treated with long-term albumin: An integrated management proposal based on a real-life study 149
Hyposplenism as a cause of pneumococcal meningoencephalitis in an adult patient with coeliac disease 149
Human albumin in the management of complications of cirrhosis. 148
A web-based group treatment for patients with alcoholic liver diseases at the time of the COVID-19 pandemic 148
Real-world experience with long-term albumin in patients with cirrhosis and ascites 141
null 138
Predictors of clinical courses in patients wih acutely decompensated cirrhosis. An external validation of the PREDICT study 137
Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin. A proposal for a personalized management based on real-world experience 136
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology 136
Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature 136
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 134
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1-receptor in a rat model of CCl4-induced advanced cirrhosis. 134
Approach and management of dysnatremias in cirrhosis 134
Albumin: Indications in chronic liver disease 133
Predictors of clinical trajectories in patients admitted for acutely decompensated cirrhosis: An external validation of the PREDICT study 131
Long‐term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial 130
Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease 128
Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant 127
Pro: The Role of Albumin in Pre–Liver Transplant Management 127
Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference 124
Defining aging phenotypes and related outcomes: Clues to recognize frailty in hospitalized older patients 120
Pattern of in-hospital changes in drug use in the older people from 2010 to 2016 120
Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis 119
Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease 118
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial 117
The Use of Rifaximin in Patients With Cirrhosis 117
Management of ascites in patients with cirrhosis: An update 116
Management of cirrhotic patients with ascites. 111
Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial 110
Living alone as an independent predictor of prolonged length of hospital stay and non-home discharge in older patients 109
Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects 107
Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database 105
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium 101
Prevention of cirrhosis complications: Looking for potential disease modifying agents 98
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis 95
Managing Multiorgan Failure in Acute on Chronic Liver Failure 93
null 88
Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. 87
Albumin in hospitalized patients with complications of cirrhosis: Not a suit for all seasons 83
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF) 73
The role and indications of albumin in advanced liver disease 73
null 59
Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701] (Journal of Hepatology (2020) 72(4) (688–701), (S0168827819306968), (10.1016/j.jhep.2019.11.009)) 51
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study 44
Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults 33
Long-term albumin treatment for decompensated cirrhosis in Italy: A propensity score-matched, retrospective, real-world chart analysis 31
Personalised Long‐Term Albumin Treatment Based on Three‐Month Ascites Response in Patients With Decompensated Cirrhosis 25
PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study 24
null 3
null 3
null 1
Totale 15.367
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.112
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.112
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021630 0 0 0 0 0 0 0 0 0 37 55 538
2021/20221.390 157 27 63 84 118 80 35 142 56 74 403 151
2022/20231.415 111 220 77 140 94 114 42 91 235 44 120 127
2023/2024679 32 72 53 80 38 132 31 45 19 36 95 46
2024/20252.460 107 358 207 203 316 138 122 95 96 209 168 441
2025/20267.074 762 611 575 558 607 335 1.532 255 1.301 538 0 0
Totale 15.367